A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed…

Overview of attention for article published in Experimental Hematology & Oncology, August 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#16 of 299)
High Attention Score compared to outputs of the same age (85th percentile)
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

news: 1 news outlet

twitter: 9 X users

Citations

dimensions_citation: 10 Dimensions

Readers on

mendeley: 56 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

Clarithromycin Plus Bortezomib May Be Ineffective, Toxic in Multiple Myeloma

Oncology Nurse Advisor , 31 Aug 2018

August 31, 2018 Reviewing a medication schedule with a patient. Clarithromycin plus bortezomib does not confer any additional…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.